BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26745241)

  • 21. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.
    de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O
    Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
    Lal S; Zarei M; Chand SN; Dylgjeri E; Mambelli-Lisboa NC; Pishvaian MJ; Yeo CJ; Winter JM; Brody JR
    Sci Rep; 2016 Sep; 6():33323. PubMed ID: 27616351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
    Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
    Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
    Do K; Wilsker D; Ji J; Zlott J; Freshwater T; Kinders RJ; Collins J; Chen AP; Doroshow JH; Kummar S
    J Clin Oncol; 2015 Oct; 33(30):3409-15. PubMed ID: 25964244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
    Lallo A; Frese KK; Morrow CJ; Sloane R; Gulati S; Schenk MW; Trapani F; Simms N; Galvin M; Brown S; Hodgkinson CL; Priest L; Hughes A; Lai Z; Cadogan E; Khandelwal G; Simpson KL; Miller C; Blackhall F; O'Connor MJ; Dive C
    Clin Cancer Res; 2018 Oct; 24(20):5153-5164. PubMed ID: 29941481
    [No Abstract]   [Full Text] [Related]  

  • 29. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
    Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the
    Kong A; Good J; Kirkham A; Savage J; Mant R; Llewellyn L; Parish J; Spruce R; Forster M; Schipani S; Harrington K; Sacco J; Murray P; Middleton G; Yap C; Mehanna H
    BMJ Open; 2020 Mar; 10(3):e033009. PubMed ID: 32184305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
    Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
    Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
    Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
    Wang B; Sun L; Yuan Z; Tao Z
    Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and Characterization of a Wee1 Kinase Degrader.
    Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
    Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
    Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
    ACS Chem Biol; 2016 Jul; 11(7):2066-7. PubMed ID: 27304454
    [No Abstract]   [Full Text] [Related]  

  • 38. Not so WEE: targeting G₂/M to kill mesothelioma cells.
    Dent P
    Cancer Biol Ther; 2014 Apr; 15(4):351-2. PubMed ID: 24496096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
    Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
    J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.